Follow us

Archives News

Nature’s Scientific Reports publishes an article describing the quantification of novel radio-enhancer AGuIX® developed in brain metastases

NH TherAguix (NHT), announced the publication in the peer-reviewed journal Scientific Reports, part of the Nature group, of an article describing a method for quantifying its next-generation radio-enhancer, AGuIX®, after tumor targeting. The article highlights the MRI biomarker properties of AGuIX® in addition to its radio-enhancing properties when combined with radiotherapy.

View Newsletter


NH TherAguix announces the release of a new clinical batch for it’s drug AGuIX manufactured by CARBOGEN AMCIS

MEYLAN, France, BUBENDORF, Switzerland (November 3rd, 2021) – NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.

See more

€13M A series funding

NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance – Grenoble/Lyon/Paris (France) – 11 April 2019

View Press Release